Biotech founder: AI gave me a 10-100x productivity boost in rare-disease drug design
zakkohane · x · 2026-09-23
A scientist and biotech founder argues "AGI is here," citing his program developing an allele-specific knockdown oligo (ASO/siRNA) for a progressive pediatric neurological rare disease.
- He quarterbacks the whole process with a tag team of Claude and GPT for data analysis, hypothesis generation, and consultations
- His key technique: red-teaming the two models against each other with identical prompts and file sets
- Using oligo design as an example, he estimates a 10-100x productivity improvement, while admitting the number isn't precisely quantified
A rare first-hand account of AI reshaping real drug-development workflows, with a transferable dual-model cross-checking method.
More from AGI Musings
- Google researcher's refugee childhood story pushback on the teen drop-out-to-SF founder narrative — satnam6502 · 2026-09-23
- Miles Brundage worries AI info flood is breaking our cognitive defenses — Miles_Brundage · 2026-09-23
- AI safety researcher David Krueger: CEO doom claims lack credibility, but transparency research is badly needed — DavidSKrueger · 2026-09-23
- AI Safety Researcher David Krueger on Extinction Risk, CEOs and Regulation — DavidSKrueger · 2026-09-23
- AI slop reveals what hiring and performance reviews should actually measure — LadyAshBorg · 2026-09-23
- AI use in math papers jumped from 1.39% to 14.09% in six months, arXiv study finds — rohanpaul_ai · 2026-09-23